Clinical Trial

A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

Name: A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate — clinical trial record (NCT06941480)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to find out whether 177Lu-DTPA-SC16.56 is a safe treatment for people with small-cell lung cancer or neuroendocrine prostate cancer

Protocol Amendment History 5 amendments

This ClinicalTrials.gov record has been amended 5 times since 2025-04-16; most recent amendment 2026-04-13.

Trial Details

NCT Number	NCT06941480
Lead Sponsor	Memorial Sloan Kettering Cancer Center
Conditions	Neuroendocrine Tumor of the Lung, Neuroendocrine Carcinoma of Lung, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma of Prostate
Enrollment	12 participants
Start Date	2026-09
Primary Completion	2030-05 (estimated)
Study Completion	2030-05 (estimated)
Updated on ClinicalTrials.gov	2026-08-06